EnVivo names Christopher Burnley CBO
This article was originally published in Scrip
EnVivo Pharmaceuticals, a company dedicated to developing novel CNS therapies, has appointed Christopher Burnley chief business officer. Mr Burnley was previously a founder and CEO of VetRx, a biotechnology start-up to develop human biologics for use in companion animals. Before forming VetRx, he served as executive vice-president and chief operating officer of Phenomix Corporation.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.